Martinez 6,7 , Maria Galn 8,9* , Affiliation: 1 Group of Endocrinology, Diabetes and Nutrition, Institut de Recerca Sant Pau, 08041 Barcelona, Spain 2 CIBER of Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain Email: [email protected] ORCID: Josep Julve 1,2* Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is a complex chronic metabolic dysfunction of the liver influenced by both genetic and non-genetic factors [1]
AOD 9604 is the right peptide for someone who is already metabolically functional, who wants to address specific fat compartments, and who cannot tolerate or is not a clinical candidate for GLP-1 therapy
Unfortunately, this is a huge misnomer
Garland Science/BIOS Scientific Publishers , 203228
Edited by Guo-Qiang Chen Supplementary information Rights and permissions Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made
